Subject of file
Shire Pharmaceuticals Ireland Limited
file no.3576
active2019-10-19 – 2019-10-19
authorities1
spend areas0
Lane I
Solo awards
€190k
awarded across 1 sole-awardee contract
The only credibly per-supplier-attributable money in this dossier — eTenders names a single awardee.
Lane II
Framework participations
0
multi-supplier frameworks · ceiling exposure €0
Per-supplier earnings cannot be derived — call-off splits between co-suppliers aren't in the source data. Read the count, not the money.
Lobbying register
23 matches
1 Sep, 2020 to 31 Dec, 2020
· Lobbyist: Shire Pharmaceuticals Ireland Limited
1 May, 2020 to 31 Aug, 2020
· Lobbyist: Shire Pharmaceuticals Ireland Limited
1 Jan, 2020 to 30 Apr, 2020
· Lobbyist: Shire Pharmaceuticals Ireland Limited
1 Sep, 2019 to 31 Dec, 2019
· Lobbyist: Shire Pharmaceuticals Ireland Limited
1 May, 2019 to 31 Aug, 2019
· Lobbyist: Shire Pharmaceuticals Ireland Limited
1 Jan, 2019 to 30 Apr, 2019
· Lobbyist: Shire Pharmaceuticals Ireland Limited
1 Sep, 2018 to 31 Dec, 2018
· Lobbyist: Hanover Media Strategy Limited
· Client: SHIRE PHARMACEUTICALS IRELAND LIMITED|BLOCK 2 & 3 MIESIAN PLAZA 50 - 58 BAGGOT STREET LOWER DUBLIN 2
Creation of national policy to increase availability of Orphan Medicinal Products
1 Sep, 2018 to 31 Dec, 2018
· Lobbyist: Shire Pharmaceuticals Ireland Limited
1 May, 2018 to 31 Aug, 2018
· Lobbyist: Shire Pharmaceuticals Ireland Limited
1 May, 2018 to 31 Aug, 2018
· Lobbyist: Hanover Media Strategy Limited
· Client: SHIRE PHARMACEUTICALS IRELAND LIMITED|BLOCK 2 & 3 MIESIAN PLAZA 50 - 58 BAGGOT STREET LOWER DUBLIN 2
Creation of national policy to increase availability of Orphan Medicinal Products
1 Jan, 2018 to 30 Apr, 2018
· Lobbyist: Hanover Media Strategy Limited
· Client: SHIRE PHARMACEUTICALS IRELAND LIMITED|BLOCK 2 & 3 MIESIAN PLAZA 50 - 58 BAGGOT STREET LOWER DUBLIN 2
Creation of national policy to increase availability of Orphan Medicinal Products
1 Jan, 2018 to 30 Apr, 2018
· Lobbyist: Shire Pharmaceuticals Ireland Limited
1 Sep, 2017 to 31 Dec, 2017
· Lobbyist: Hanover Media Strategy Limited
· Client: SHIRE PHARMACEUTICALS IRELAND LIMITED|BLOCK 2 & 3 MIESIAN PLAZA 50 - 58 BAGGOT STREET LOWER DUBLIN 2
Creation of national policy to increase availability of Orphan Medicinal Products
1 Sep, 2017 to 31 Dec, 2017
· Lobbyist: Hume Brophy
· Client: Shire Pharmaceuticals Ireland Limited|BLOCK 2 & 3 MIESIAN PLAZA 50 - 58 BAGGOT STREET LOWER DUBLIN 2
Access to treatments for rare diseases
1 Sep, 2017 to 31 Dec, 2017
· Lobbyist: Shire Pharmaceuticals Ireland Limited
Request to meet at World Economic Forum, Davos, January 2018
1 Sep, 2017 to 31 Dec, 2017
· Lobbyist: Shire Pharmaceuticals Ireland Limited
Request to meet at World Economic Forum, Davos, January 2018
1 Sep, 2017 to 31 Dec, 2017
· Lobbyist: Shire Pharmaceuticals Ireland Limited
Request for a meeting with Simon Harris TD to discuss personalisation and the Irish Rare Disease Plan
1 May, 2017 to 31 Aug, 2017
· Lobbyist: Shire Pharmaceuticals Ireland Limited
1 May, 2017 to 31 Aug, 2017
· Lobbyist: Hanover Media Strategy Limited
· Client: SHIRE PHARMACEUTICALS IRELAND LIMITED|BLOCK 2 & 3 MIESIAN PLAZA 50 - 58 BAGGOT STREET LOWER DUBLIN 2
Rare Disease Medicines
1 May, 2017 to 31 Aug, 2017
· Lobbyist: Hume Brophy
· Client: Shire Pharmaceuticals Ireland Limited|BLOCK 2 & 3 MIESIAN PLAZA 50 - 58 BAGGOT STREET LOWER DUBLIN 2
Access to treatments for rare diseases
1 Jan, 2017 to 30 Apr, 2017
· Lobbyist: Shire Pharmaceuticals Ireland Limited
Meeting request to discuss Irish Rare Disease Plan & access to rare disease treatments
1 Jan, 2017 to 30 Apr, 2017
· Lobbyist: Shire Pharmaceuticals Ireland Limited
Access to treatments for rare diseases & Irish Rare Disease Plan
1 Jan, 2017 to 30 Apr, 2017
· Lobbyist: Shire Pharmaceuticals Ireland Limited
Meeting to discuss Shire investment in Ireland
Sole-awardee contracts. Awarded values reflect actual money paid to this supplier.
| Date |
Authority |
Contract |
Procedure |
Estimated |
Awarded |
| 2019-10-19 |
Beaumont Hospital |
The supply of Human Albumin Solution Products for Beaumont Hospital.
TED
CAN
|
Open Procedure |
€250k |
€190k |
Framework participations
0 records
No multi-supplier framework participations on record.